EconPapers    
Economics at your fingertips  
 

Advances In Immunotherapy-Emerging Treatment Paradigms for Cancer

Amaira Goyal

International Journal of Scientific Research in Science and Technology, 2025, vol. 12, issue 4, 239-246

Abstract: Background: Lung cancer predominantly comprises non-small cell lung cancer (NSCLC), which accounts for a large portion of cancer cases and remains a leading cause of cancer- related mortality worldwide. Traditional chemotherapy provides limited benefit and is associated with significant toxicity, highlighting the need for more effective and targeted treatment such as monoclonal antibodies. Objective: The aim of this study to evaluate the effectiveness, quality of life effects, and adverse event profile of nivolumab, a PD-1 immune checkpoint inhibitor, compared to standard first-line therapy in patients with advanced NSCLC. Methods: A randomized controlled trial includes 60 patients diagnosed with stage III and IV NSCLC. Patient are assigned to receive either nivolumab (240 mg i.v biweekly) (Group A) or platinum-based chemotherapy (Group B). Tumor size, quality of life, and side effects are assessed over a 12- week period using imaging and clinical evaluation. Results: Tumor size reduces by 40% in Group A and 25% in Group B. Quality of life scores for Group A increased from 60 to 70, while Group B values declined from 60 to 52. Group A exhibited fewer and less severe adverse effects than Group B, with no instances of Grade 4 toxicity recorded in Group A, in contrast to two cases of Grade 4 toxicity in Group B. Conclusion: The study's findings indicate that, unlike conventional chemotherapy protocols, nivolumab exhibited more efficacy and safety, favorably affecting tumor response and improving patient's quality of life while minimizing treatment-related side effects. This is a crucial therapeutic alternative for advanced NSCLC.

Keywords: Non-Small Cell Lung Cancer; Nivolumab; Monoclonal Antibody; Immunotherapy; Chemotherapy (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://ijsrst.com/home/article/view/IJSRST251280 Abstract page (text/html)
https://ijsrst.com/home/article/download/IJSRST251280/IJSRST251269 Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:etm:ijsrst:v12:y2025:i4:id:1008

DOI: 10.32628/IJSRST251280

Access Statistics for this article

More articles in International Journal of Scientific Research in Science and Technology from Technoscience Academy
Bibliographic data for series maintained by Pankaj Sharma ().

 
Page updated 2026-07-27
Handle: RePEc:etm:ijsrst:v12:y2025:i4:id:1008